Where cancer genomics should go next

A clinician's perspective

Arash Rafii Tabrizi, C. Touboul, H. Al Thani, Karsten Suhre, Joel Malek

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Large-scale, genomic studies of specific tumors such as The Cancer Genome Atlas have provided a better understanding of the alterations of pathways involved in the development of solid tumors including glioblastoma, breast cancer, ovarian and endometrial cancers, colon cancer and lung squamous cell carcinoma. This tremendous effort of the scientific community has confirmed the view that cancer actually represents a wide variety of diseases originating from different organs. These studies showed that TP53 and PI3KCA are the two most mutated genes in all types of cancers and that 30-70%of all solid tumors harbor potentially 'actionable'mutationsthatcanbe exploitedfor patientstratificationor treatmentoptimization. Translationof thishuge oncogenomic data set to clinical application in personalized medicine programs is now the main challenge for the future. The gap between our basic knowledge and clinical application is still wide. Closing the gap will require translational personalized trials, which may initiate a radical change in our routine clinical practice in oncology.

Original languageEnglish
JournalHuman Molecular Genetics
Volume23
Issue numberR1
DOIs
Publication statusPublished - 2014

Fingerprint

Genomics
Neoplasms
Colonic Neoplasms
Precision Medicine
Atlases
Glioblastoma
Endometrial Neoplasms
Ovarian Neoplasms
Squamous Cell Carcinoma
Lung Neoplasms
Genome
Breast Neoplasms
Genes

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Where cancer genomics should go next : A clinician's perspective. / Tabrizi, Arash Rafii; Touboul, C.; Al Thani, H.; Suhre, Karsten; Malek, Joel.

In: Human Molecular Genetics, Vol. 23, No. R1, 2014.

Research output: Contribution to journalReview article

@article{23593ba3ee864ade972dfd9fd95be322,
title = "Where cancer genomics should go next: A clinician's perspective",
abstract = "Large-scale, genomic studies of specific tumors such as The Cancer Genome Atlas have provided a better understanding of the alterations of pathways involved in the development of solid tumors including glioblastoma, breast cancer, ovarian and endometrial cancers, colon cancer and lung squamous cell carcinoma. This tremendous effort of the scientific community has confirmed the view that cancer actually represents a wide variety of diseases originating from different organs. These studies showed that TP53 and PI3KCA are the two most mutated genes in all types of cancers and that 30-70{\%}of all solid tumors harbor potentially 'actionable'mutationsthatcanbe exploitedfor patientstratificationor treatmentoptimization. Translationof thishuge oncogenomic data set to clinical application in personalized medicine programs is now the main challenge for the future. The gap between our basic knowledge and clinical application is still wide. Closing the gap will require translational personalized trials, which may initiate a radical change in our routine clinical practice in oncology.",
author = "Tabrizi, {Arash Rafii} and C. Touboul and {Al Thani}, H. and Karsten Suhre and Joel Malek",
year = "2014",
doi = "10.1093/hmg/ddu234",
language = "English",
volume = "23",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "R1",

}

TY - JOUR

T1 - Where cancer genomics should go next

T2 - A clinician's perspective

AU - Tabrizi, Arash Rafii

AU - Touboul, C.

AU - Al Thani, H.

AU - Suhre, Karsten

AU - Malek, Joel

PY - 2014

Y1 - 2014

N2 - Large-scale, genomic studies of specific tumors such as The Cancer Genome Atlas have provided a better understanding of the alterations of pathways involved in the development of solid tumors including glioblastoma, breast cancer, ovarian and endometrial cancers, colon cancer and lung squamous cell carcinoma. This tremendous effort of the scientific community has confirmed the view that cancer actually represents a wide variety of diseases originating from different organs. These studies showed that TP53 and PI3KCA are the two most mutated genes in all types of cancers and that 30-70%of all solid tumors harbor potentially 'actionable'mutationsthatcanbe exploitedfor patientstratificationor treatmentoptimization. Translationof thishuge oncogenomic data set to clinical application in personalized medicine programs is now the main challenge for the future. The gap between our basic knowledge and clinical application is still wide. Closing the gap will require translational personalized trials, which may initiate a radical change in our routine clinical practice in oncology.

AB - Large-scale, genomic studies of specific tumors such as The Cancer Genome Atlas have provided a better understanding of the alterations of pathways involved in the development of solid tumors including glioblastoma, breast cancer, ovarian and endometrial cancers, colon cancer and lung squamous cell carcinoma. This tremendous effort of the scientific community has confirmed the view that cancer actually represents a wide variety of diseases originating from different organs. These studies showed that TP53 and PI3KCA are the two most mutated genes in all types of cancers and that 30-70%of all solid tumors harbor potentially 'actionable'mutationsthatcanbe exploitedfor patientstratificationor treatmentoptimization. Translationof thishuge oncogenomic data set to clinical application in personalized medicine programs is now the main challenge for the future. The gap between our basic knowledge and clinical application is still wide. Closing the gap will require translational personalized trials, which may initiate a radical change in our routine clinical practice in oncology.

UR - http://www.scopus.com/inward/record.url?scp=84906836267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906836267&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddu234

DO - 10.1093/hmg/ddu234

M3 - Review article

VL - 23

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - R1

ER -